Pharmacokinetics, safety, and tolerability of ceftibuten-ledaborbactam etzadroxil in participants with renal impairment. (PubMed, Antimicrob Agents Chemother) - Sep 29, 2026 - P1 | "No deaths, serious adverse events, or treatment-related adverse events leading to study drug discontinuation were reported. These results indicate that dose adjustment of ceftibuten-ledaborbactam etzadroxil will be required for patients with reduced renal function.This study is registered with ClinicalTrials.gov as NCT05488678."
Journal • PK/PD data • Chronic Kidney Disease • Infectious Disease • Nephrology • Renal Disease
|
|
Carlos Fernando de Oliveira; Kamal A Hamed; Karine Litherland; Kathryn Lowe; Marc Engelhardt; Paul C McGovern; Penny Fatato; Thomas Marbury
|